| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2006.
NEWS |
Identity Crisis: Finding, Defining, and Integrating Biomarkers Still a Challenge
| The first 10% of the full text of this article appears below. |
As the understanding of cancer evolves, so too has the search for better ways to diagnose and treat the disease. Biomarkers have been used to measure exposure, risk, treatment selection, prognosis, best dose of an agent, early response, residual disease, metastasis, and drug toxicity. But what to one researcher is a biomarker that assesses the presence of disease is to another a classifier for selecting patients likely to respond to a specific treatment, and the difference in meaning and intent between these two examples highlights one of the major challenges in field.
"The first challenge we have is to have a vocabulary we agree on," Gordon Mills, M.D., chair of
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Rubio-Viqueira, H. Mezzadra, M. E. Nielsen, A. Jimeno, X. Zhang, C. Iacobuzio-Donahue, A. Maitra, M. Hidalgo, and S. Altiok Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays Mol. Cancer Ther., February 1, 2007; 6(2): 515 - 523. [Abstract] [Full Text] [PDF]
|
|